Minerva Neurosciences (NERV) Non-Current Assets (2013 - 2026)
Minerva Neurosciences posted quarterly Non-Current Assets of $14.9 million for Q1 2026, little changed year-on-year from $14.9 million in Q1 2025, and little changed on a QoQ basis from $14.9 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Non-Current Assets data on file, last reported at $14.9 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets changed 0.32% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $59.7 million (changed 0.38% YoY), and the FY2025 full-year result was $14.9 million, changed 0.04% from the prior year.
- Non-Current Assets for Q1 2026 stood at $14.9 million, roughly flat from $14.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $15.1 million in Q3 2025 and bottomed at $14.9 million in Q4 2025.
- The 5-year median for Non-Current Assets is $14.9 million (2023), against an average of $14.9 million.
- The widest annual swing landed in 2022, when Non-Current Assets sank 50.5%; it then rose 1.32% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $14.9 million in 2022, then dropped by 0.21% to $14.9 million in 2023, then decreased by 0.15% to $14.9 million in 2024, then decreased by 0.04% to $14.9 million in 2025, then rose by 0.34% to $14.9 million in 2026.
- The last three Non-Current Assets figures came in at $14.9 million (Q1 2026), $14.9 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | 14.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.92 Mn |
| Dec 31, 2025 | 14.87 Mn |
| Sep 30, 2025 | 15.07 Mn |
| Jun 30, 2025 | 14.87 Mn |
| Mar 31, 2025 | 14.87 Mn |
| Dec 31, 2024 | 14.87 Mn |
| Sep 30, 2024 | 14.88 Mn |
| Jun 30, 2024 | 14.88 Mn |
| Mar 31, 2024 | 14.89 Mn |
| Dec 31, 2023 | 14.90 Mn |
| Sep 30, 2023 | 14.91 Mn |
| Jun 30, 2023 | 14.91 Mn |
| Mar 31, 2023 | 14.92 Mn |
| Dec 31, 2022 | 14.93 Mn |
| Sep 30, 2022 | 14.92 Mn |
| Jun 30, 2022 | 14.92 Mn |
| Mar 31, 2022 | 14.92 Mn |
| Dec 31, 2021 | 14.92 Mn |
| Sep 30, 2021 | 30.12 Mn |
| Jun 30, 2021 | 30.10 Mn |
| Mar 31, 2021 | 30.14 Mn |
| Dec 31, 2020 | 30.19 Mn |
| Sep 30, 2020 | 30.23 Mn |
| Jun 30, 2020 | 30.28 Mn |
| Mar 31, 2020 | 30.32 Mn |
| Dec 31, 2019 | 30.36 Mn |
| Sep 30, 2019 | 49.40 Mn |
| Jun 30, 2019 | 49.44 Mn |
| Mar 31, 2019 | 49.48 Mn |
| Dec 31, 2018 | 49.12 Mn |
| Sep 30, 2018 | 49.12 Mn |
| Jun 30, 2018 | 49.13 Mn |
| Mar 31, 2018 | 49.13 Mn |
| Dec 31, 2017 | 54.16 Mn |
| Sep 30, 2017 | 59.42 Mn |
| Jun 30, 2017 | 49.31 Mn |
| Mar 31, 2017 | 49.08 Mn |
| Dec 31, 2016 | 49.08 Mn |
| Sep 30, 2016 | 49.08 Mn |
| Jun 30, 2016 | 49.09 Mn |
| Mar 31, 2016 | 49.09 Mn |
| Dec 31, 2015 | 49.10 Mn |
| Sep 30, 2015 | 50.51 Mn |
| Jun 30, 2015 | 58.55 Mn |
| Mar 31, 2015 | 49.10 Mn |
| Dec 31, 2014 | 49.11 Mn |
| Sep 30, 2014 | 49.10 Mn |
| Jun 30, 2014 | 52.44 Mn |
| Dec 31, 2013 | 27.36 Mn |